Navigation Links
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Date:3/24/2008

ion. This can decrease the efficacy of the current medication and may compromise future treatment options. To date, studies have shown that multiple mutations are required to develop BARACLUDE(R) (entecavir) resistance.

"These long-term BARACLUDE data continue to support the observations seen in the first years of treatment and are reflective of BARACLUDE's high genetic barrier to resistance," said Helena Brett-Smith, M.D., Group Director of Clinical Research at Bristol-Myers Squibb. "More importantly, we believe the data support BARACLUDE as an important initial treatment choice for chronic hepatitis B, which is a disease that results in a large global health burden."

About the Analysis

More than 700 patients across six studies initiated therapy on BARACLUDE and were monitored for treatment response and resistance.

The year five analysis expands upon previous analyses, adding in information on patients who received treatment with BARACLUDE during the fifth year of follow-up (n=108 for patients in nucleoside-naive studies and n=33 for patients in lamivudine-refractory studies).

In this comprehensive analysis, all patients enrolled in Bristol-Myers Squibb clinical trials ETV-014, -015, -022, -027, -026 and -901 who experienced a virologic breakthrough(1) or whose virus had not yet reached undetectable levels(2) at weeks 48, 96, 144, 192, 240 or end of dosing, were sequenced to determine if any changes occurred in the genetic code of the virus that would result in resistance or loss of effectiveness of BARACLUDE.

Nucleoside-naive patients in this analysis were initially treated with BARACLUDE 0.5 mg in studies ETV-022 and -027 and continued treatment with BARACLUDE 1 mg by enrolling in study ETV-901 with a treatment gap of less than or equal to 35 days. Lamivudine-refractory patients in this analysis initiated therapy on BARACLUDE 1 mg in studies ETV-014, -015, and -026 and continued treatment in study ETV-901 with a treatment
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
2. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
3. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
4. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
5. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
6. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  TeamHealth Medical Call Center (THMCC), a premier ... lines, announces its newly formed Clinical Advisory Committee. ... leaders, provides clinical expertise to advance THMCC,s purpose ... hospital clients, physician clients and patients. ... imperative to continuously advance our services and improve ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, ... treatment of viral infections, today announced that it has ... 9200, its investigational, once daily, oral therapy for the ... healthy, HCV-infected patients and is designed to assess both ... 9200 is a first-in-class drug for the treatment of ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 23, 2007 - CytoGenix, Inc. (CYGX.OB),announced today that ... update on preclinical animal data for DNA vaccines ... 2007,DNA Vaccines conference to be held in Malaga, ... comments, "We have successfully conducted tests of,synDNA(TM) based ...
... VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix Inc. ... by ITTEC Stem, Inc. at the University of ... for stem cells demonstrate the vital importance of ... This is the,first series of tests using AAGP(TM) ...
Cached Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 ... C.R. Bard, Inc., continue to move forward in a ... District of West Virginia, Bernstein Liebhard LLP reports. ... denied a request by C.R. Bard to seal emails ... trade secrets and other confidential, proprietary information about its ...
(Date:5/23/2013)... New York, NY (PRWEB) May 23, 2013 ... http://bit.ly/Z4m6UI , Canadian tech start-ups are increasingly seeing ... deals with larger US-based companies, according to ... business development engine. , The company has compiled ... entitled Borderless Investments. The findings of the research have ...
(Date:5/23/2013)... May 23, 2013 EnvirOasis, the leader ... and ESCO market is pleased to announce its new ... Listed LED products. EnvirOasis has been a market ... and retrofit kits and has recently brought to market ... (Light Emitting Diode) is energy efficient lighting technology which ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... as badly as methamphetamine or crack cocaine, a new ... ,meth mouth, or ,coke mouth, it is startling to ... less the same," said Dr. Mohamed Bassiouny, a professor ... Dentistry in Philadelphia. Methamphetamine, crack cocaine and soda ...
Breaking Medicine News(10 mins):Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... SOUTH SAN FRANCISCO, Calif., July 7 Catalyst Biosciences, ... research and license agreement with MedImmune, the global biologics ... that specifically degrade or modulate two targets, one of ... , Catalyst will receive undisclosed upfront licensing fees, full-time ...
... is a fully equipped bio-safety level 2 laboratory dedicated exclusively ... Affairs for Medizone. "This new laboratory is located in ... the country and will provide a primary research and development ... now a clear path to commercialization with its lead product, ...
... 2009 AMERIGROUP Corporation (NYSE: AGP ) today ... quarter ended June 30, 2009, at approximately 6:00 a.m. Eastern ... Eastern Time on the same day, AMERIGROUP,s management will host ... information. , , To listen to the call, dial ...
... GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... of other natural and organic dairy products, invites you to come ... the first pitch before the Chicago Cubs take on the Atlanta ... this official "Lifeway Day with the Cubs," the local kefir manufacturer ...
... July 7 CSC (NYSE: CSC ) today ... in multiple categories of Celent,s 2009 Insurance Software Deal Trends ... research and advisory firm, reported in the Life/Health Edition that ... Processing with 56 percent of the deals in 2007 and ...
... 7 Rho Luxfeyr does not want to be labeled as ... that she offers via her Web site ( http://rho-luxfeyr.com ) extend ... tellers focus on predicting the future, which is really no help ... can be constructed or changed by will or intent," said Luxfeyr. ...
Cached Medicine News:Health News:Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics 2Health News:Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontario, Canada. 2Health News:AMERIGROUP Corporation to Discuss Second Quarter Earnings on July 31 2Health News:Giant Bugs Invade Wrigley Field 2Health News:CSC Cited as a Leading Technology Provider in Celent Insurance Software Study 2Health News:Unique Intuitive Service Helps Clients Improve Their Lives 2
... monochromatic and chromatic correction for the focal ... completely flat images for observation and photomicrography ... of wavelengths up to the near UV ... glass types of low autofluorescence makes these ...
... The CFI Fluor 20x Water ... physiology and brain research where the ... exposed living tissue or brain slice. ... bright fluorescent signals with a numberical ...
Inquire...
... 63x/1.25 Oil Ph3 Antiflex is ... contrast. This method reveals structures ... such as cells adhering to ... dish. Moreover, this objective is ...
Medicine Products: